Insulin Lispro Sanofi (Insulin Lispro)

• Insulin Lispro Sanofi is a rapid‑acting insulin analogue used in the management of diabetes mellitus by providing post‑prandial glucose control.
• Diabetes mellitus type 1: improves post‑meal glucose levels and reduces hyperglycaemia.
• Diabetes mellitus type 2: complements basal insulin or oral agents to achieve target glycaemic control.
• Gestational diabetes (off‑label): may be considered when other therapies are insufficient, under specialist supervision.

• Insulin Lispro binds to insulin receptors on muscle and adipose cells, rapidly stimulating glucose uptake and inhibiting hepatic glucose production. This promotes glycogen synthesis and mimics the physiological first‑phase insulin response after meals, resulting in swift reduction of post‑prandial blood glucose levels.

Common Side Effects

• Hypoglycaemia: low blood glucose episodes, especially if meals are missed or dosing is excessive.
• Injection site reactions: redness, swelling, or itching at the injection site.
• Weight gain: modest increase due to improved glucose utilisation.
• Lipodystrophy: localized fat tissue changes with repeated injections.
• Headache: mild to moderate intensity.
• Nausea: occasional gastrointestinal discomfort.

Serious or Rare Side Effects

• Severe hypoglycaemia: can lead to loss of consciousness, seizures, or injury.
• Anaphylactic reaction: life‑threatening allergic response with rash, swelling, or breathing difficulty.
• Angioedema: rapid swelling of face, lips, or tongue.
• Serum sickness‑like reaction: fever, rash, arthralgia.
• Hypokalemia: low potassium levels, especially with high insulin doses.
• Ketoacidosis (if insulin omitted): metabolic emergency requiring urgent care.

Before using Insulin Lispro Sanofi, consider the following precautions:

• Dose adjustment: individualise dosing based on blood glucose monitoring and carbohydrate intake.
• Renal impairment: monitor closely as insulin clearance may be reduced.
• Hepatic impairment: use with caution; altered glucose metabolism may occur.
• Pregnancy and lactation: discuss potential risks and benefits with a healthcare professional.
• Hypoglycaemia risk: educate patients on recognising and treating low blood glucose.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Major Interactions (Avoid)

• Beta‑blockers: may mask hypoglycaemia symptoms, requiring careful monitoring.
• Sulfonylureas or meglitinides: increase risk of severe hypoglycaemia when combined.
• Glucagon: concurrent use can cause unpredictable glucose responses.

Moderate Interactions (Monitor Closely)

• ACE inhibitors: may potentiate insulin’s glucose‑lowering effect.
• Thiazide diuretics: can raise blood glucose, necessitating dose adjustments.
• Oral contraceptives: may affect insulin sensitivity and glucose control.
• Corticosteroids: can increase insulin requirements.
• Alcohol: may potentiate hypoglycaemia, especially with delayed meals.